A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2018
At a glance
- Drugs AG 881 (Primary) ; Ivosidenib (Primary)
- Indications Glioma
- Focus Biomarker; Pharmacodynamics
- Acronyms Window
- Sponsors Agios Pharmaceuticals
- 16 Nov 2018 According to an Agios Pharmaceuticals media release, updates from the study are being presented as part of a trials in progress poster, at the Society for Neuro-Oncology (SNO) Annual Meeting.
- 31 Aug 2018 Biomarkers information updated
- 01 Jun 2018 According to an Agios Pharmaceuticals media release, data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018.